Name (Synonyms) | Correlation | |
---|---|---|
drug508 | Calcium Channel Blockers Wiki | 0.45 |
drug2515 | Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki | 0.45 |
drug176 | Angiotensin receptor blocker Wiki | 0.45 |
drug1650 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) Wiki | 0.45 |
drug2507 | Thiazide or Thiazide-like diuretics Wiki | 0.45 |
drug1649 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) Wiki | 0.45 |
drug2024 | Random Donor Plasma Wiki | 0.45 |
drug803 | ECCO2R Wiki | 0.45 |
drug1648 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) Wiki | 0.45 |
drug151 | Aluminum adjuvant Wiki | 0.45 |
drug2513 | Thrombin Generation Assay (TGA) Wiki | 0.45 |
drug652 | Convalescent Plasma Transfusion Wiki | 0.32 |
drug2121 | SAB-185 Wiki | 0.32 |
drug2413 | TAK-788 Wiki | 0.26 |
drug2381 | Supportive Care Wiki | 0.26 |
drug53 | ACE inhibitor Wiki | 0.26 |
drug1883 | Povidone-Iodine Wiki | 0.22 |
drug576 | Clazakizumab Wiki | 0.20 |
drug159 | Anakinra Wiki | 0.17 |
Name (Synonyms) | Correlation | |
---|---|---|
D005759 | Gastroenteritis NIH | 0.32 |
D017250 | Caliciviridae Infections NIH | 0.32 |
D004211 | Disseminated Intravascular Coagulation NIH | 0.22 |
D020141 | Hemostatic Disorders NIH | 0.13 |
D001778 | Blood Coagulation Disorders NIH | 0.13 |
D006973 | Hypertension NIH | 0.12 |
D016638 | Critical Illness NIH | 0.06 |
D014777 | Virus Diseases NIH | 0.05 |
D055371 | Acute Lung Injury NIH | 0.04 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.04 |
D007239 | Infection NIH | 0.03 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0005521 | Disseminated intravascular coagulation HPO | 0.22 |
HP:0001928 | Abnormality of coagulation HPO | 0.13 |
HP:0000822 | Hypertension HPO | 0.12 |
There are 5 clinical trials
This trial investigates whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses.
Description: The aim of this study is to follow enrolled participants until 221 occurrences of all-cause allograft loss, defined as return to dialysis, allograft nephrectomy, re-transplantation, eGFR <15 mL/min/1.73 m2 or death from any cause have been observed. The analysis will be a stratified log rank test of the effect of treatment on all-cause composite allograft loss, with stratification factors of dichotomized baseline eGFR (25-45 mL/min/1.73 m2 versus >45-65 mL/min/1.73 m2), baseline proteinuria, treatment for early (within 6 months of transplant) ABMR rejection episodes (yes/no), and treatment for late (greater than 6 months post transplant) ABMR rejection episodes (yes/no). Surviving subjects without allograft loss will be censored at the time of their last assessment.
Measure: Incidence of all cause composite allograft loss Time: Five yearsA total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
Measure: All active AEs within 0-7 days after each dose Time: 7 daysDescription: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
Measure: All non-active collection AEs within 0-28(30) days after each dose Time: 28(30) daysThis proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
Description: Supplemental oxygen requirement to maintain oxygen saturation >90% stable or decreased without escalation of respiratory measures (addition of CPAP, initiation of mechanical ventilation)
Measure: No increase in oxygen requirement and no increase in respiratory support measures Time: 48 hoursDescription: 25% decrease in noted baseline elevations of serum ferritin, LDH, CRP, and d-dimer.
Measure: Improvement in Cytokine Storm markers Time: 72 hoursDescription: Subjects discharged from hospital without the need for mechanical ventilation
Measure: No requirement for mechanical ventilation Time: Day 5 (120 hours)COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.
Description: viral load as measured by real time polymerase chain reaction (PCR)
Measure: Change in viral load in the oral and nasopharyngeal cavity Time: Day 0, 2, 3, 7, 14Description: Visual analogue score 1-5 per symptom via a smartphone app
Measure: Symptom severity in primary participants and co-residents Time: Days 0 to 14Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.
Description: Incidence and severity of other adverse events and severe adverse events (SAE)
Measure: Number of Participants Having Adverse Events Time: 29 DaysDescription: transfusion-related adverse events
Measure: Number of Participants Having Transfusion-Related Adverse Events Time: 29 DaysDescription: Incidence and severity of adverse events and SAEs from Screening through Study Day 90
Measure: Number of Participants Having Adverse Events Time: 90 DaysDescription: SARS-CoV-2 binding (ELISA) and neutralizing (PRNT80) antibody titers from Screening through Study Day 90
Measure: Pharmacokinetics from screening to day 90 Time: 90 Days